Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 10, No. 1-4, 2012
Issue release date: April 2012
Section title: Paper
Free Access
Neurodegenerative Dis 2012;10:238–241

Regulation of Physiologic Actions of LRRK2: Focus on Autophagy

Ferree A.a · Guillily M.a · Li H.c, d · Smith K.a · Takashima A.f · Squillace R.e · Weigele M.e · Collins J.J.c, d · Wolozin B.a, b
Departments of aPharmacology, bNeurology, and cBiomedical Engineering, Boston University School of Medicine, Boston, Mass., dHoward Hughes Medical Institute, Chevy Chase, Md., and eAriad Pharmaceuticals, Cambridge, Mass., USA; fDepartment of Aging Neurobiology, National Center for Geriatrics and Gerontology, Aichi, Japan
email Corresponding Author

Benjamin Wolozin, MD, PhD

Departments of Pharmacology and Neurology

Boston University School of Medicine

72 East Concord St., R614, Boston, MA 02118-2526 (USA)

Tel. +1 617 414 2652, E-Mail bwolozin@bu.edu


  1. Greggio E, Cookson MR: Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions. ASN Neuro 2009;1(pii):e00002.
    External Resources
  2. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM: Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 2005;102:16842–16847.
  3. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, Dawson TM: Parkinson’s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 2007;16:223–232.
  4. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, Ahmad R, Miller DW, Kesavapany S, Singleton A, Lees A, Harvey RJ, Harvey K, Cookson MR: Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006;23:329–341.
  5. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, Cookson MR: The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 2007;357:668–671.
  6. Xiong Y, Coombes CE, Kilaru A, Li X, Gitler AD, Bowers WJ, Dawson VL, Dawson TM, Moore DJ: GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet 2010;6:e1000902.
  7. Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, Daniels V, Lewis P, Jain S, Ding J, Syed A, Thomas KJ, Baekelandt V, Cookson MR: The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 2008;283:16906–16914.
  8. Berger Z, Smith KA, Lavoie MJ: Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry 2010;49:5511–5523.
  9. Chan D, Citro A, Cordy JM, Shen GC, Wolozin B: Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2). J Biol Chem 2011;286:16140–16149.
  10. Gehrke S, Imai Y, Sokol N, Lu B: Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 2010;466:637–641.
  11. Plowey ED, Cherra SJ 3rd, Liu YJ, Chu CT: Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem 2008;105:1048–1056.
  12. Saha S, Guillily MD, Ferree A, Lanceta J, Chan D, Ghosh J, Hsu CH, Segal L, Raghavan K, Matsumoto K, Hisamoto N, Kuwahara T, Iwatsubo T, Moore L, Goldstein L, Cookson M, Wolozin B: LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 2009;29:9210–9218.
  13. Faith JJ, Hayete B, Thaden JT, Mogno I, Wierzbowski J, Cottarel G, Kasif S, Collins JJ, Gardner TS: Large-scale mapping and validation of Escherichia coli transcriptional regulation from a compendium of expression profiles. PLoS Biol 2007;5:e8.
    External Resources
  14. di Bernardo D, Thompson MJ, Gardner TS, Chobot SE, Eastwood EL, Wojtovich AP, Elliott SJ, Schaus SE, Collins JJ: Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks. Nat Biotechnol 2005;23:377–383.
  15. Guillily M, Li H, Latourelle JC, Pyenson N, Richter L, Raghavan G, Saha S, Dusonchet J, Lee-Armandt JP, Glicksman M, Yue Z, Myers RH, Collins JJ, Wolozin G: A reverse engineered Parkinson’s disease gene regulatory network identifies RGS2 as a direct modulator of LRRK2 activity. Submitted.
  16. Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, Schellenberg GD: Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci USA 2003;100:9980–9985.
  17. Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F, Clackson T: Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther 2011;10:1059–1071.